Clinical Trial Update: Effect of ANKASCIN 568-P Products Regulating Blood Lipid [NA]

View source ↗

Summary

A clinical trial update indicates ANKASCIN 568-P is being studied for regulating blood lipids in hyperlipidemia, with the trial currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipidemia

Drugs mentioned

• ANKASCIN 568-P

Snippet

Sponsor: SunWay Biotech Co., LTD. | Conditions: Hyperlipidemias | NA | Status: RECRUITING